Marshall Wace
JNCE

Marshall Wace’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Marshall Wace’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-39,339
Closed -$119K – 3961
2022
Q2 		$119K Buy
+39,339
New +$191K ﹤0.01% 3253
2021
Q4 		– Sell
-169,686
Closed -$1.26M – 4445
2021
Q3 		$1.26M Sell
169,686
-81,792
-33% -$507K 0.01% 1868
2021
Q2 		$1.71M Buy
251,478
+156,739
+165% +$1.3M 0.01% 1509
2021
Q1 		$973K Buy
+94,739
New +$1.04M ﹤0.01% 1676
2020
Q3 		– Sell
-84,369
Closed -$582K – 2023
2020
Q2 		$582K Sell
84,369
-171,770
-67% -$927K ﹤0.01% 1154
2020
Q1 		$1.22M Sell
256,139
-217,426
-46% -$1.25M 0.01% 754
2019
Q4 		$4.13M Buy
+473,565
New +$2.56M 0.03% 592
2019
Q1 		– Sell
-25,999
Closed -$88K – 2139
2018
Q4 		$88K Buy
+25,999
New +$121K ﹤0.01% 1388

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Marshall Wace's JNCE Position: Q3 2022 in Review

Marshall Wace sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 39,339 shares — an estimated $119K sold.

Marshall Wace first reported a position in JNCE in Q4 2018 and held it in 8 quarters. The position peaked at $4.13M in Q4 2019. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

  • Marshall Wace reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Marshall Wace sold 39,339 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $119K.
  • Marshall Wace first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2018 and held it in 8 quarters.
  • Marshall Wace's Jounce Therapeutics, Inc. Common Stock position peaked at $4.13M in Q4 2019.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Marshall Wace's 13F filing for Q3 2022, filed 14 Nov 2022.